Phase 2/3 trial in treatment-refractory Mycobacterium avium Complex continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of.
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease
On track to announce Phase 2 clinical data.
MENLO PARK, Calif. (BUSINESS WIRE) AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious